drugset / Trial / NCT04789304
A Study to Test How Healthy Men Tolerate Different Doses of BI 1595043
RandomizedParallel-groupTriple-blindTreatment
Summary
The primary objectives of this trial are to investigate safety and tolerability of BI 1595043 in healthy male subjects following administration of multiple rising doses over 14 days. Secondary objectives are the exploration of pharmacokinetics (PK) of BI 1595043 after single and multiple dosing.
Timeline
- Start
- 2021-04-01
- Primary completion
- 2022-01-14
- Completion
- 2022-01-14
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BI 1595043 | Unknown | 15 mg | Oral |
| Subject | BI 1595043 | Unknown | 30 mg | Oral |
| Subject | BI 1595043 | Unknown | 60 mg | Oral |
| Subject | Midazolam | Small molecule | — | — |
Indications
No indication recorded.